Testosterone Cypionate FAERS Safety Signals: What Post-Market Surveillance Data Actually Shows

What FAERS Is and Why It Matters for Testosterone Cypionate

The FDA Adverse Event Reporting System is the primary U.S. Database for post-market drug safety surveillance. It collects voluntary reports from healthcare professionals, patients, and manufacturers after a drug reaches the market. For testosterone cypionate, FAERS data has shaped two decades of labeling decisions and clinical practice guidelines.

How Reports Enter FAERS

Manufacturers must submit reports of serious adverse events within 15 calendar days. Healthcare providers and patients submit voluntarily through MedWatch. This creates an inherent reporting bias: serious events are overrepresented, and the absence of a signal does not prove safety. The FDA uses disproportionality analyses (reporting odds ratios) to identify statistical signals above background noise.

FAERS Limitations in Context

FAERS cannot establish causation. It flags correlations. A single patient event generates a "case," and the same patient may appear multiple times. Denominator data (total prescriptions filled) is not captured in FAERS itself, so the FDA cross-references with claims databases and programs like FDA Sentinel to estimate true incidence rates. For testosterone cypionate specifically, the Sentinel System Active Risk Identification and Analysis (ARIA) program has been used to evaluate cardiovascular safety signals flagged in FAERS [1].

Cardiovascular Safety Signals: The Central Controversy

Cardiovascular adverse events represent the most scrutinized FAERS signal for testosterone cypionate. Reports of myocardial infarction, stroke, and venous thromboembolism prompted the FDA to issue a 2015 safety communication requiring label changes across all testosterone products.

The 2014 FDA Advisory Committee and Label Change

In September 2014, the FDA convened an advisory committee after two retrospective studies raised alarms. A 2013 JAMA study (N=8,709 male veterans with coronary angiography) reported a 29% higher absolute rate of adverse outcomes in testosterone-treated men [2]. A separate 2014 PLoS ONE analysis (N=55,593) found a twofold increase in MI risk in men over age 65 within 90 days of filling a testosterone prescription [3].

The advisory committee voted 20 to 1 that testosterone products should carry a cardiovascular warning. The resulting label revision, finalized in March 2015, added: "Long-term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men."

TRAVERSE: The Trial That Changed the Calculus

The FDA mandated a randomized controlled cardiovascular outcomes trial. The result was TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men), published in the New England Journal of Medicine in 2023. This was the first large-scale, placebo-controlled trial designed to evaluate major adverse cardiovascular events (MACE) in hypogonadal men.

TRAVERSE enrolled 5,246 men aged 45 to 80 with hypogonadism and preexisting cardiovascular disease or elevated CV risk. Over a mean follow-up of 33 months, the incidence of MACE (cardiovascular death, nonfatal MI, nonfatal stroke) was 7.0% in the testosterone group vs. 7.3% in the placebo group (HR 0.96; 95% CI 0.78 to 1.17), meeting the prespecified non-inferiority margin [4].

That result did not eliminate concern entirely. TRAVERSE also showed a higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury (2.3% vs. 1.5%) in the testosterone arm [4].

Polycythemia: The Most Pharmacologically Predictable Signal

Testosterone stimulates erythropoietin production in the kidneys. Rising hematocrit is not an idiosyncratic reaction; it is a dose-dependent pharmacological effect. FAERS data reflects this, with polycythemia and erythrocytosis among the most frequently reported events for testosterone cypionate.

Clinical Thresholds and Monitoring

The Endocrine Society 2018 guidelines recommend checking hematocrit at baseline, 3 to 6 months after initiation, and annually thereafter. The threshold for intervention is a hematocrit exceeding 54%. At that level, the guidelines recommend dose reduction, therapeutic phlebotomy, or temporary discontinuation [5].

Real-World Incidence

In the T-Trials (Testosterone Trials), which enrolled 788 men aged 65 and older with low testosterone and treated them with transdermal testosterone gel for 12 months, hematocrit exceeded 54% in approximately 4% of treated men compared to 0% on placebo [6]. Injectable testosterone cypionate, which produces higher peak serum levels than gels, carries a proportionally higher polycythemia risk. A 2019 retrospective cohort study of 3,422 men on intramuscular testosterone found that 11.2% developed hematocrit above 54% within the first year [7].

Hepatic Safety Signals

Liver-related FAERS reports for testosterone cypionate include elevated transaminases, cholestatic jaundice, and rare cases of peliosis hepatis. The clinical context matters here. Oral 17-alpha-alkylated androgens (methyltestosterone, fluoxymesterone) carry a well-documented hepatotoxicity risk because of first-pass liver metabolism. Injectable testosterone cypionate bypasses first-pass metabolism, and its hepatotoxicity profile is substantially different.

What the Label Says

The current testosterone cypionate prescribing information includes hepatic adverse reactions in the Warnings and Precautions section, citing prolonged use of high doses of androgens as a risk factor for peliosis hepatis and hepatic neoplasms [8]. This language largely carries forward from older labeling that grouped all androgen formulations together.

Disproportionality Analysis

A 2020 pharmacovigilance analysis of FAERS data for all testosterone products found that hepatic events had a reporting odds ratio (ROR) of 1.8 (95% CI 1.4 to 2.3) compared to the full FAERS database background rate. When restricted to injectable esters only (cypionate and enanthate), the ROR dropped to 1.2 (95% CI 0.9 to 1.6), suggesting the class-level signal was driven primarily by oral formulations [9].

Psychiatric and Behavioral Signals

FAERS includes reports of aggression, irritability, mania, depression, and suicidal ideation associated with testosterone cypionate. The pharmacological plausibility is established: testosterone modulates serotonergic, dopaminergic, and GABAergic neurotransmission.

Dose-Response Relationship

Supraphysiologic testosterone levels (typically above 1,500 ng/dL) are more strongly associated with mood and behavioral disturbance than replacement-dose therapy targeting the mid-normal range of 450 to 700 ng/dL. A controlled crossover study by Pope et al. (N=56 healthy men) found that doses of 600 mg/week of testosterone cypionate (roughly 3 to 6 times a standard TRT dose) produced manic or hypomanic symptoms in 16% of participants, while none in the placebo phase developed such symptoms [10].

Signal vs. Noise

At replacement doses (100 to 200 mg every 1 to 2 weeks), the T-Trials showed no statistically significant difference in depressive symptoms or aggression scores between testosterone and placebo groups over 12 months [6]. FAERS psychiatric reports likely capture a mix of misuse, supratherapeutic dosing, and genuine idiosyncratic reactions at standard doses. The Endocrine Society specifically recommends against prescribing testosterone to men without documented hypogonadism, in part to reduce these risks [5].

Venous Thromboembolism (VTE)

Deep vein thrombosis and pulmonary embolism appear as distinct FAERS signals. The proposed mechanism links testosterone-induced polycythemia (increased blood viscosity) and possible direct effects on the coagulation cascade to VTE risk.

Quantifying the Risk

A 2019 self-controlled case series using U.K. Clinical Practice Research Datalink (N=39,622 men) found a VTE rate ratio of 1.25 (95% CI 1.07 to 1.46) in the first 6 months of testosterone therapy compared to unexposed periods in the same individuals [11]. TRAVERSE confirmed a numerical increase in pulmonary embolism (0.9% vs. 0.5%) but was not powered specifically for VTE as a primary endpoint [4].

The FDA Label Update

Since 2014, the testosterone cypionate label has included a warning about VTE risk and instructs prescribers to evaluate patients who develop signs or symptoms of DVT or PE during therapy. The current label recommends discontinuation if a VTE event occurs [8].

Prostate Safety

The relationship between testosterone and prostate cancer has been debated for decades. FAERS includes reports of elevated PSA, benign prostatic hyperplasia progression, and prostate cancer diagnoses in men on testosterone cypionate.

What Large Trials Show

TRAVERSE included a prostate safety substudy. Over the trial period, prostate cancer incidence was numerically similar between groups (testosterone 0.19 events per 100 person-years vs. Placebo 0.26 events per 100 person-years) [4]. The T-Trials found a modest mean PSA increase of 0.4 ng/mL in the testosterone group compared to no change in the placebo group [6]. The Endocrine Society recommends PSA screening at baseline and at 3 to 12 months after starting therapy, with urological referral for PSA increases exceeding 1.4 ng/mL over 12 months [5].

How the FDA Uses FAERS Data to Update Labels

FAERS does not operate in isolation. When a disproportionality signal reaches a predefined threshold, FDA reviewers initiate a multi-step evaluation.

The Signal-to-Label Pipeline

Step one: the signal is detected through automated data mining using the Multi-Item Gamma Poisson Shrinker (MGPS) algorithm. Step two: an epidemiologist reviews the individual case narratives for clinical plausibility. Step three: if warranted, the FDA requests a Sentinel analysis for incidence estimation using real-world claims data. Step four: a safety review may result in a Drug Safety Communication, an advisory committee meeting, or a label revision under the Supplemental New Drug Application process.

For testosterone cypionate, this pipeline produced the 2015 class-wide cardiovascular warning, the 2014 VTE label update, and the mandate for the TRAVERSE trial. The 2023 TRAVERSE results are now under review and may lead to further label modifications [4].

International Regulatory Comparison

The European Medicines Agency (EMA) conducted a parallel review in 2014 and concluded that the evidence did not support a cardiovascular warning for testosterone products in the EU, though the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that prescribers monitor hematocrit and cardiovascular risk factors [12]. This regulatory divergence between the FDA and EMA persists as of 2026.

What Clinicians Should Monitor Based on FAERS Data

Current FAERS signals, validated by trial data, support a structured monitoring protocol for men on testosterone cypionate.

Baseline Assessment

Before initiating therapy: hematocrit, hemoglobin, fasting lipid panel, hepatic function tests (AST, ALT, bilirubin), PSA, cardiovascular risk assessment, and screening for obstructive sleep apnea (a known complication of testosterone therapy) [5].

Ongoing Surveillance

At 3 to 6 months: repeat hematocrit (withhold if above 54%), testosterone trough level (target 400 to 700 ng/dL), PSA, and liver enzymes. Annually thereafter: hematocrit, PSA, lipid panel, and reassessment of cardiovascular risk. The Endocrine Society recommends against prescribing testosterone to men who desire fertility in the near term, as exogenous testosterone suppresses spermatogenesis through HPG axis negative feedback [5].

Men on testosterone cypionate with a hematocrit above 50% at any monitoring visit should have their injection frequency and dose reevaluated before the next scheduled injection.